Physician profile
Abdul Razack
NPI 1144294406
$5,730.38
in general payments reported to CMS, 2019-2025
24 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $363 · 2021: $891 · 2022: $1,154 · 2023: $1,007 · 2024: $634 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014 · Education: $15.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.79 |
| Education | $15.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,143.97 | 2019-2025 | |
| Madrigal Pharmaceuticals | $430.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $350.38 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $326.84 | 2019-2025 | Livdelzi |
| Ardelyx, INC. | $248.45 | 2025 | Ibsrela |
| Celgene Corporation | $169.17 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $164.15 | 2021-2022 | |
| Novo Nordisk INC | $149.20 | 2025 | Wegovy |
| Sirtex Medical INC | $118.39 | 2024 | Sir-Spheres Microspheres |
| Regeneron Healthcare Solutions, INC. | $90.76 | 2022-2023 | Dupixent |
| Braintree Laboratories, INC. | $73.12 | 2019-2021 | |
| Genzyme Corporation | $69.55 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.95 | 2021-2023 | Entyvio |
| Allergan, INC. | $51.16 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $47.41 | 2021-2023 | Ocaliva |
| Boston Scientific Corporation | $35.39 | 2023-2025 | Resolution 360 Clip, Resolution 360 Ultra Clip |
| Ipsen Biopharmaceuticals, INC | $33.15 | 2025 | Iqirvo |
| Qol Medical, LLC | $25.38 | 2023 | Sucraid |
| Aimmune Therapeutics, INC. | $21.08 | 2025 | Vowst |
| Alnylam Pharmaceuticals INC. | $16.87 | 2021 | |
| Shionogi INC | $16.48 | 2019 | |
| Organon LLC | $14.27 | 2023 | Renflexis |
| Merck Sharp & Dohme LLC | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Razack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.